Arcutis (AQRT) Has Significantly More Upside, roflumilast is Key Driver - Mizuho Securities Bullish on Stock
Tweet Send to a Friend
Mizuho Securities analyst Uy Ear reiterated a Buy rating and $57.00 price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT). The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
